Therefore, to test if MSU-42011 can enhance the effects of a clinically approved MEK inhibitor, selumetinib [15], we implanted murine LL2 lung cancer cells, a Kras/Nras mutant cell line [36], into the flank of C57BL/6 mice (1 × 106 cells/mouse). This evidence concerns the gene MAP2K7 and lung carcinoma.